Loading...
XSTO
SPRINT
Market cap4mUSD
May 28, Last price  
0.44SEK
1D
-1.34%
1Q
-68.94%
Jan 2017
-98.59%
IPO
-97.10%
Name

Sprint Bioscience AB

Chart & Performance

D1W1MN
P/E
—
P/S
0.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
35.94%
Rev. gr., 5y
14.37%
Revenues
66m
+30.02%
2,367,9401,588,3382,371,0004,609,9267,726,61134,992,08223,967,00017,936,00033,541,00016,885,00035,114,00083,00050,485,00065,641,000
Net income
-18m
L+4,072.83%
-1,376,930-3,545,289-4,387,000-11,463,623-15,500,1014,540,852-10,663,000-22,216,000-22,744,000-46,233,000-25,352,000-60,170,000-438,000-18,277,000
CFO
-23m
L
-2,292,000-3,566,000-10,758,973833,5457,934,875-23,052,000-19,083,000-28,003,000-32,223,000-40,117,000-59,054,00022,871,000-23,356,000
Earnings
Aug 26, 2025

Profile

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
URL
https://www.sprintbioscience.com/
IPO date
Nov 07, 2014
Employees
27
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
65,641
30.02%
50,485
60,725.30%
83
-99.76%
Cost of revenue
28,337
8,698
60,992
Unusual Expense (Income)
NOPBT
37,304
41,787
(60,909)
NOPBT Margin
56.83%
82.77%
Operating Taxes
Tax Rate
NOPAT
37,304
41,787
(60,909)
Net income
(18,277)
4,072.83%
(438)
-99.27%
(60,170)
137.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
2
17,903
BB yield
0.00%
-76.97%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(25,056)
(49,984)
(29,543)
Cash flow
Cash from operating activities
(23,356)
22,871
(59,054)
CAPEX
(1,297)
(2,454)
Cash from investing activities
(1,297)
(2,454)
Cash from financing activities
(225)
24
17,903
FCF
36,965
39,780
(60,291)
Balance
Cash
25,056
49,934
29,493
Long term investments
50
50
Excess cash
21,774
47,460
29,539
Stockholders' equity
(264,399)
(246,121)
(245,685)
Invested Capital
273,671
273,895
273,873
ROIC
13.63%
15.26%
ROCE
402.33%
150.45%
EV
Common stock shares outstanding
69,820
69,810
42,059
Price
1.58
-9.20%
1.74
214.65%
0.55
-88.47%
Market cap
110,316
-9.18%
121,469
422.25%
23,259
-86.00%
EV
85,260
71,485
(6,284)
EBITDA
38,262
42,234
(60,291)
EV/EBITDA
2.23
1.69
0.10
Interest
40
Interest/NOPBT
0.11%